FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912201582> ?p ?o ?g. }

• W2912201582 abstract "355 Background: The RESORCE trial proved survival benefit of regorafenib on advanced hepatocellular carcinoma (aHCC) in the limiting cohort. This study aimed to investigate the efficacy of hepatic arterial infusion chemotherapy (HAIC) as second-line treatment in patients with aHCC who are unfit for regorafenib. Methods: We studied consecutive 159 patients with aHCC treated with sorafenib in our institution from June 2009 to March 2018. We divided them into two groups according to the eligibility for RESORCE trial (Rego or non-Rego group) and investigated the efficacy of HAIC as post-sorafenib treatment. Moreover, we also analyzed the prognostic factors in each group. Results: When sorafenib treatment failed, 63 patients (39.6%) fulfilled key inclusion criteria of the RESORCE trial and were considered as fit for regorafenib treatment (Rego group). Among 96 remaining patients (non-Rego group), 34 patients (35.4%) were treated with HAIC after sorafenib. The objective response and the median progression-free survival of HAIC were 38.2% and 3.9 months, which were independent of the efficacy or treatment duration of sorafenib. The median survival of HAIC after sorafenib was 11.3 months which was significantly longer than that of 62 patients without HAIC (4.7 months; P = 0.023). Four factors, HAIC (HR 0.516), Child-Pugh A (HR 0.362), tumor size ≥35mm (HR 1.959), and AFP ≥200 (HR 1.728), were identified as independent prognostic factors after sorafenib in multivariate analysis. In Rego group, 14 patients were actually treated with regorafenib and their survival after sorafenib was longer than that of the patients without regorafenib and with HAIC (P < 0.01 and P < 0.01, respectively). In Rego group, regorafenib (HR 0.152), extrahepatic lesions (HR 2.160), and ≥10 intra-hepatic lesions (HR 2.099) were identified as prognostic factors after sorafenib in multivariate analysis. Conclusions: HAIC showed promising tumor response and patients’ outcome for the patients who are unfit for regorafenib. Further investigation is needed to compare HAIC with ramucirumab, cabozantinib or nivolumab." @default.
• W2912201582 created "2019-02-21" @default.
• W2912201582 creator A5017380559 @default.
• W2912201582 creator A5043073600 @default.
• W2912201582 creator A5058321251 @default.
• W2912201582 creator A5069065380 @default.
• W2912201582 creator A5076591862 @default.
• W2912201582 creator A5086023651 @default.
• W2912201582 date "2019-02-01" @default.
• W2912201582 modified "2023-09-23" @default.
• W2912201582 title "Hepatic arterial infusion chemotherapy after sorafenib treatment in patients with advanced hepatocellular carcinoma who are unfit for regorafenib." @default.
• W2912201582 doi "https://doi.org/10.1200/jco.2019.37.4_suppl.355" @default.
• W2912201582 hasPublicationYear "2019" @default.
• W2912201582 type Work @default.
• W2912201582 sameAs 2912201582 @default.
• W2912201582 citedByCount "1" @default.
• W2912201582 countsByYear W29122015822021 @default.
• W2912201582 crossrefType "journal-article" @default.
• W2912201582 hasAuthorship W2912201582A5017380559 @default.
• W2912201582 hasAuthorship W2912201582A5043073600 @default.
• W2912201582 hasAuthorship W2912201582A5058321251 @default.
• W2912201582 hasAuthorship W2912201582A5069065380 @default.
• W2912201582 hasAuthorship W2912201582A5076591862 @default.
• W2912201582 hasAuthorship W2912201582A5086023651 @default.
• W2912201582 hasConcept C121608353 @default.
• W2912201582 hasConcept C126322002 @default.
• W2912201582 hasConcept C143998085 @default.
• W2912201582 hasConcept C2776248978 @default.
• W2912201582 hasConcept C2776694085 @default.
• W2912201582 hasConcept C2778019345 @default.
• W2912201582 hasConcept C2778695046 @default.
• W2912201582 hasConcept C2779984678 @default.
• W2912201582 hasConcept C31760486 @default.
• W2912201582 hasConcept C526805850 @default.
• W2912201582 hasConcept C71924100 @default.
• W2912201582 hasConcept C90924648 @default.
• W2912201582 hasConceptScore W2912201582C121608353 @default.
• W2912201582 hasConceptScore W2912201582C126322002 @default.
• W2912201582 hasConceptScore W2912201582C143998085 @default.
• W2912201582 hasConceptScore W2912201582C2776248978 @default.
• W2912201582 hasConceptScore W2912201582C2776694085 @default.
• W2912201582 hasConceptScore W2912201582C2778019345 @default.
• W2912201582 hasConceptScore W2912201582C2778695046 @default.
• W2912201582 hasConceptScore W2912201582C2779984678 @default.
• W2912201582 hasConceptScore W2912201582C31760486 @default.
• W2912201582 hasConceptScore W2912201582C526805850 @default.
• W2912201582 hasConceptScore W2912201582C71924100 @default.
• W2912201582 hasConceptScore W2912201582C90924648 @default.
• W2912201582 hasLocation W29122015821 @default.
• W2912201582 hasOpenAccess W2912201582 @default.
• W2912201582 hasPrimaryLocation W29122015821 @default.
• W2912201582 hasRelatedWork W1975331378 @default.
• W2912201582 hasRelatedWork W2558335336 @default.
• W2912201582 hasRelatedWork W2592068656 @default.
• W2912201582 hasRelatedWork W2938267598 @default.
• W2912201582 hasRelatedWork W2947116423 @default.
• W2912201582 hasRelatedWork W2993085971 @default.
• W2912201582 hasRelatedWork W3108220068 @default.
• W2912201582 hasRelatedWork W3134717436 @default.
• W2912201582 hasRelatedWork W4246597360 @default.
• W2912201582 hasRelatedWork W4286762368 @default.
• W2912201582 isParatext "false" @default.
• W2912201582 isRetracted "false" @default.
• W2912201582 magId "2912201582" @default.
• W2912201582 workType "article" @default.